$VTRS News

Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?

Viatris (VTRS) Q2 2026 Earnings Call Transcript

VTRS Q2 Deep Dive: China Growth, Pipeline Progress, and Margin Concerns Shape Outlook

Viatris (VTRS) Is Down 6.4% After Raising 2026 Guidance And Completing Major Buyback Program

Viatris (VTRS) Stock May Be Below Fair Value Despite FDA Patch Approval

Viatris (VTRS) Raises 2026 Guidance, Is The 11% Gap Below Fair Value Enough?

Viatris (VTRS) Stock Sees Modest Fair Value Lift After Q1 Results And Pipeline Progress

Viatris Inc (VTRS) (Q2 2026) Earnings Call Highlights: Strong Growth and Raised Guidance Amid ...

Viatris Inc. (VTRS) Q2 2026 Earnings Call Transcript

VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump

Viatris Inc. 2026 Q2 - Results - Earnings Call Presentation

Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics

Viatris (VTRS) Beats Q2 Earnings and Revenue Estimates

Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q2 CY2026

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

Viatris Reports Second-Quarter 2026 Financial Results

Viatris Q2 Adj. EPS $0.69 Beats $0.60 Estimate, Sales $3.756B Beat $3.675B Estimate

Viatris Raises FY2026 Adj EPS Guidance from $2.33-$2.47 to $2.45-$2.49 vs $2.44 Est; Raises FY2026 Sales Guidance from $14.450B-$14.950B to $14.550B-$14.950B vs $14.783B Est

Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Viatris Gears Up to Report Q2 Earnings: What's in the Cards?